Get the Stockscreener App
4.61
3.60%
0.16
After Hours:
4.32
-0.29
-6.29%
Trisalus Life Sciences Inc stock is traded at $4.61, with a volume of 66,776.
It is up +3.60% in the last 24 hours and down -12.19% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$4.45
Open:
$4.47
24h Volume:
66,776
Relative Volume:
1.44
Market Cap:
$130.44M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.29%
1M Performance:
-12.19%
6M Performance:
-52.72%
1Y Performance:
-9.96%
1-Day Range:
$4.18
$4.825
1-Week Range:
$3.97
$4.825
52-Week Range:
$3.32
$10.42
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TriSalus Life Sciences, Inc. Announces Appointment of Riad Salem to its Scientific Advisory Board - Marketscreener.com
TriSalus Life Sciences adds oncology expert to SAB By Investing.com - Investing.com South Africa
TriSalus Life Sciences adds oncology expert to SAB By Investing.com - Investing.com Canada
TriSalus Life Sciences adds oncology expert to SAB - Investing.com India
TriSalus Life Sciences adds oncology expert to SAB - Investing.com
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board - StockTitan
Magnetar Financial LLC Has $1.05 Million Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) - Defense World
Terrain Minerals Welcomes New Major Investor - TipRanks
TrivarX Boosts Board with Healthcare Expertise - TipRanks
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com UK
Progeny 3 Inc. Raises Stock Holdings in Sixth Street Specialty Lending, Inc. (NYSE:TSLX) - Defense World
940,831 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Purchased by Great Point Partners LLC - Defense World
Telesis Bio Inc (TBIO) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX” - ForexTV.com
TRxADE Health rebrands as Scienture Holdings with new ticker SCNX - Investing.com
Investing in Telesis Bio Inc (TBIO) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Farallon Capital Management LLC Buys Shares of 2,000 TransMedics Group, Inc. (NASDAQ:TMDX) - Defense World
Trupanion: Great Business, But It Is Time To Cash Out (Rating Downgrade) - Seeking Alpha
TriSalus reports breakthrough in liver tumor treatment By Investing.com - Investing.com Canada
TriSalus reports breakthrough in liver tumor treatment - Investing.com India
Hood River Capital Management LLC Acquires New Position in TransMedics Group, Inc. (NASDAQ:TMDX) - Defense World
Keeping an Eye on Tourmaline Bio Inc (TRML) After Insider Trading Activity - Knox Daily
Financial Metrics Check: Traws Pharma Inc. (TRAW)’s Ratios for Trailing Twelve Months - The Dwinnex
TriSalus reports breakthrough in liver tumor treatment - Investing.com
TriSalus: PEDD method via TriNav Infusion System aided penetration of GM - TipRanks
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System - StockTitan
35,000 Shares in Trupanion, Inc. (NASDAQ:TRUP) Purchased by Dalton Investments Inc. - MarketBeat
Inspire Investing LLC Makes New $772,000 Investment in Transcat, Inc. (NASDAQ:TRNS) - MarketBeat
Texas Permanent School Fund Corp Has $1.08 Million Stake in Trupanion, Inc. (NASDAQ:TRUP) - Defense World
Trupanion (NASDAQ:TRUP) Shares Gap Up on Analyst Upgrade - MarketBeat
Bank of America Raises Trupanion (NASDAQ:TRUP) Price Target to $56.00 - MarketBeat
Telesis Bio Inc (TBIO) can make a big difference with a little luck - SETE News
Highbridge Capital Management LLC Buys Shares of 214,545 TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - MarketBeat
Contrasting Cerus (NASDAQ:CERS) & TriSalus Life Sciences (NASDAQ:TLSI) - Defense World
Traws Pharma Announces Key Approvals and Reverse Stock Split at 2024 Special Meeting - MyChesCo
Blair William & Co. IL Decreases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX) - MarketBeat
Ratios in Focus: Analyzing Telesis Bio Inc (TBIO)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Highbridge Capital Management LLC Invests $1.18 Million in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Oppenheimer - Defense World
Oppenheimer Initiates Coverage of TriSalus Life Sciences (TLSI) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI) - MarketBeat
Oppenheimer initiates TriSalus stock at outperform on liver cancer opportunity - Investing.com India
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Update - MarketBeat
TriSalus Life Sciences Inc (TLSI) CEO Buys Shares By GuruFocus - Investing.com Canada
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Buys 7,520 Shares - MarketBeat
TriSalus Life Sciences CEO buys $75k in company stock - Investing.com
TriSalus Life Sciences CEO buys $24,850 in company stock - Investing.com
TriSalus Life Sciences CEO buys $24,850 in company stock - Investing.com India
Trisalus Life Sciences director sells shares worth $49 - Investing.com
Trisalus Life Sciences director sells shares worth $49 By Investing.com - Investing.com Australia
Trisalus Life Sciences director sells shares worth $49 By Investing.com - Investing.com Canada
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):